Find out more about Antibody-Drug Conjugates (ADCs) in our upcoming webinar scheduled for Tuesday, October 29 at 8am PST/11am EST/3pm UK. We will be discussing DMPK considerations during discovery and early development, bioanalytical strategies to measure ADCs, immunogenicity considerations and PK/PD modeling and simulations. By registering once, you will have access to and receive updates for each webinar in the series. Register for the series here: https://lnkd.in/gnF442Jj For more information and to watch previous webinars, check out our page: https://lnkd.in/g5ACuqDp #DMPK #webinar #ADC #PKPD
关于我们
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 20,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. Services: * Synthetic, medicinal and analytical chemistry services * Biology services * DMPK services * Pharmacology services * Drug safety assessment services * Radiochemistry and isotopically labelled metabolism services * Chemical & pharmaceutical development services * Clinical development services www.pharmaron.com CRO - Contract Research Organization & CDMO - Contract Development Manufacturing Organization Library Synthesis CADD Bioorganic Chemistry Discovery Process Chemistry Radiolabelled Chemical Synthesis ChemInformatics in vitro Biology in vitro Screening Structural Biology in vivo Pharmacology Animal Disease Models ex vivo Pharmacology Biomarkers in vitro ADME in vivo PK PKPD QA Regulatory Affairs Discovery Biologics Process Chemistry API Manufacturing Material Science Formulation Development Drug Product Manufacturing Toxicology Safety Pharmacology Genetic Toxicology DART Pathology Immunotoxicity Bioanalytical 14C / Carbon-14 Radiosynthesis 3H / Tritium Radiosynthesis QWBA mARG Clinical AME Mass Balance Metabolite Profiling Microdosing Phase 0 Absolute Bioavailability DDI First-in-Human (FIH) Thorough QT(TQT) Ethnobridging
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Beijing
- 类型
- 私人持股
- 领域
- Chemistry、Biology、DMPK、Pharmacology、Chemical Development、Preclinical、Toxicology、Safety Pharmacology、Discovery、Lead Optimization、Process Development、Assay Development、ADME、Formulation、clinical pharmacology、analytical sciences、radiolabelled chemistry、accelerator mass spectrometry、radiolabelled compounds、API manufacturing、radiosynthesis、Biologics和CTG Products
地点
Pharmaron员工
动态
-
Filipa Antunes, our Senior Director of Business Development, introduces Pharmaron, who we are, and what we do at this week’s ELRIG Drug Discovery conference in London. Next stop is CPhI in Milan, 8 – 10 October. Don’t miss the opportunity to connect with our experts and explore our global API and drug product development and manufacturing capabilities to support clinical and commercial needs. Arrange a meeting via the following link - https://lnkd.in/gT7rnqwr Visit Hall 5, Booth 5F106, to learn more about our end-to-end CDMO services and state-of-the-art facilities and discuss potential collaborations. #CPHIMilan #CMC #API #drugproduct #drugdevelopment #CDMO #CRO #CPHI #ELRIG2024
-
At Pharmaron, we understand the critical importance of accurate potency testing in advancing the safety and efficacy of biologics, cell therapies, and gene therapies. Our comprehensive Cell-Based Potency Assay Services are designed to meet the highest regulatory standards, ensuring your products are ready for commercial success. With expertise in GMP-compliant assays and a proven track record of supporting approved products, we provide end-to-end solutions for every stage of assay development. We deliver results that move your project forward from initial validation to full regulatory compliance. Discover how Pharmaron can help you achieve regulatory success: https://lnkd.in/gJ3Smvyv #PotencyAssays #Biologics #CellTherapy #GeneTherapy #Innovation #RegulatoryExcellence #CDMO
-
It's Day 2 at #ELRIG2024! Thank you to everyone who attended Dr. John Maclean’s insightful talk this morning at ELRIG Drug Discovery 2024! If you’re looking for more cutting-edge research, don’t miss Pharmaron’s poster presentations at 1:00pm today. Our team is excited to share even more of our discoveries! Be sure to stop by Booth E02 to connect with us! #Pharmaron #ELRIG2024 #DrugDiscovery #ScientificResearch #LifeSciences #PharmaInnovation
-
October is Depression Awareness Month, a crucial time to focus on mental health. Depression affects over 280 million people globally, yet many remain undiagnosed. Early screening and intervention can save lives. At Pharmaron, we are proud to support scientists and companies developing innovative treatments and diagnostics to address mental health challenges, helping ensure that those affected can access the care they need. Learn more about the importance of depression screening here: https://lnkd.in/d4qCMjwm #DepressionAwareness #MentalHealthMatters #PharmaronCares #HealthcareInnovation
-
If you are attending the SABPA Biopharma conference this Saturday, October 5, in San Diego, let’s meet! Stop by our booth or request to meet with us here: https://lnkd.in/g6AECzKH SABPA Pharmaron US Lab Services #pharmaron
-
Join Pharmaron at the Boston Society’s APA conference in Cambridge, MA October 7-9. Our colleague, Stephen English, will be presenting “Qualification of Low Energy Accelerator Mass Spectrometry and Opportunities to Increase Industry Utilization.” If you’d like to arrange a meeting, let us know! Submit a request here: https://lnkd.in/e_H-x8E5 @[Stephen English](urn:li:person:_M3wLmlR7R)
-
We're excited to announce the second issue of Pharmaron's Discovery News Newsletter—your gateway to the latest breakthroughs in drug discovery. Join us as we explore cutting-edge advancements that fast-track the discovery of small molecules and other emerging modalities. This is where innovation meets impact, and you're invited to be part of the journey. Don't miss out—subscribe today to deliver each issue directly to your inbox. Please share our insights with your friends and colleagues if they are valuable. Let's drive the future of drug discovery together. #Pharmaron #DrugDiscovery #Innovation #SmallMolecules #EmergingModalities #PharmaNews #SubscribeNow #ShareTheKnowledge
-
Day one of ELRIG Drug Discovery 2024 is here, and we’re excited to welcome you to Booth E02! Come meet the Pharmaron team and learn how our scientific expertise can help accelerate your drug discovery programs. From early discovery to clinical development and beyond, we’re ready to collaborate and innovate with you! Don’t miss the chance to connect with us — we can’t wait to see you! #Pharmaron #ELRIG2024 #DrugDiscovery #ScientificExpertise #PharmaInnovation #LifeSciences
-
October is Breast Cancer Awareness Month, a time to emphasize the importance of early detection. In 2024, over 360,000 people in the U.S. will be diagnosed with breast cancer, but survival rates rise to 99% when detected early. Pharmaron is proud to support scientists and healthcare companies advancing innovations in early screening, diagnostics, and treatment. Together, we aim to improve outcomes for patients worldwide. Learn more about early detection: https://lnkd.in/gMWdGcD8 #BreastCancerAwarenessMonth #EarlyDetection #PharmaronCares #HealthcareInnovation #pharmaroncares #pharmaron